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Abstract 
Objectives: 
To investigate whether (1) there were differences between HLA-DRB1*15-positive and -
negative patients at baseline, and (2) HLA-DRB1*15-positive patients showed a greater 
development of brain and spinal cord damage, as assessed by MRI, and greater progression 
of disability, during a 5-year follow-up, compared with HLA-DRB1*15-negative patients. 
 
Methods: 
HLA-DRB1*15 typing was performed in 41 patients with primary progressive multiple 
sclerosis (PPMS) who were recruited within 5 years of symptom onset. All patients and 18 
healthy controls were studied clinically and with MRI at baseline, and every 6 months for 3 
years, and then at 5 years. Magnetization transfer ratio parameters and volumes for brain 
gray matter and normal-appearing white matter, brain T2 lesion load, and spinal cord cross-
sectional area were obtained. Patient disability was assessed at each visit using the 
Expanded Disability Status Scale and Multiple Sclerosis Functional Composite subscores. 
 
Results: 
There were no significant differences between HLA-DRB1*15-positive and -negative patients 
at baseline. HLA-DRB1*15-positive patients showed a greater decline in brain magnetization 
transfer ratio for gray matter and normal-appearing white matter (both p = 0.005) than HLA-
DRB1*15-negative patients over 5 years, while the same parameters did not change over 
time in healthy controls. HLA-DRB1*15-positive patients also showed a trend toward a faster 
increase in brain T2 lesion load than HLA-DRB1*15-negative patients (0.29 [95% confidence 
interval 0.20–0.38] vs 0.21 [0.13–0.30] mL/mo, p = 0.085) and higher T2 lesion volumes at 
all time points (average difference [95% confidence interval]: 10.58 mL [7.09–14.07], p < 
0.001) during the follow-up, after adjusting for disease duration. 
 
Conclusions: 
These findings suggest that HLA-DRB1*15 influences the progression of brain pathology in 
PPMS. 
  
The allele HLA-DRB1*15 has been associated with susceptibility to multiple sclerosis (MS).1 
It also seems to influence the phenotypic expression of the disease, regarding age at 
onset,2 cognitive disability,3 and extent of brain damage at a single time point, as detected 
by conventional and advanced MRI.4 A recent postmortem study suggests HLA-DRB1*15 is 
associated with a greater extent of spinal cord pathology in MS, mainly demyelination and 
inflammation.5 
 
The rate of progression of disability and accumulation of brain and spinal cord damage 
differs among patients with primary progressive multiple sclerosis (PPMS), especially in the 
first few years after onset.6,–8 It is unknown whether these rates are associated with specific 
genetic factors. The identification of these factors may be useful for stratification of patients 
at higher risk of progression. 
 
The question that we address in this report is whether HLA-DRB1*15 influences the rate of 
progression and the development of brain and spinal cord damage, as detected by 
conventional and advanced MRI, in patients with early PPMS during a 5-year follow-up. 
 
Methods 
Study design. 
Forty-seven patients with definite or probable PPMS9 within 5 years of symptom onset were 
studied with clinical and brain MRI assessments at baseline and every 6 months for 3 years, 
and again at 5 years. Spinal cord MRI was performed at baseline and year 2. Eighteen 
healthy controls were scanned at all time points. At each visit, patients were scored on the 
Expanded Disability Status Scale (EDSS).10 In 15 patients, the EDSS score at 5-year 
follow-up was not obtained in person but assessed by phone, because patients were too 
disabled to attend their visits. When possible, the Multiple Sclerosis Functional Composite 
subtests (i.e., the timed 25-foot walk test, the 9-Hole Peg Test, and the Paced Auditory 
Serial Addition Test) were also scored3 (see table 1 for patient characteristics at baseline). 
HLA-DRB1*15 typing on total genomic DNA, extracted from whole blood, was performed in 
41 of 47 patients as described previously.11 
 
Image acquisition and processing. 
All scans were performed on a 1.5-tesla GE Signa scanner (General Electric Co., 
Milwaukee, WI). During the study, the scanner was upgraded. The effect of the upgrade was 
considered in the statistical analysis.7 
 
The following sequences were acquired at several time points, as previously reported6,7,12: 
(1) brain magnetization transfer dual-echo spin-echo sequence, including proton density and 
T2-weighted images13; (2) brain volumetric images (3-dimensional inversion prepared fast 
spoiled gradient recall); and (3) spinal cord volumetric imaging. 
 
T2 lesion volume, magnetization transfer ratio (MTR) histogram parameters for gray matter 
(GM) and normal-appearing white matter (NAWM) (i.e., mean, peak location, and peak 
height [PH]), the percentage GM and NAWM fractions, and spinal cord cross-sectional area 
at C2-3 were obtained as previously described.6,14 See appendix e-1 on the Neurology® 
Web site at Neurology.org for further information on image acquisition and processing. 
 
Statistical analysis. 
Analysis was performed with Stata 12 statistical software (StataCorp, College Station, TX). 
Clinical and MRI differences between HLA-DRB1*15-positive and -negative patients at 
baseline were assessed using multiple linear regression, with MRI or clinical response 
variable as predictor on a patient group indicator; age, sex, or disease duration was entered 
as covariate to assess any potential confounding. Rates of change in brain and spinal cord 
MRI and clinical measures were compared between patient groups using linear mixed 
models. The linear mixed models specified a random intercept and random slope (on time), 
together with an unstructured covariance. The MRI or clinical variable was the response 
variable, and as predictors we included time from symptom onset, a subject group indicator, 
and a group × time interaction term. In addition, interaction terms between time and age, 
sex, or baseline EDSS score were added as covariates to control for potentially confounding 
baseline differences between the 2 patient groups. Where regression residuals showed 
deviation from normality, confidence intervals (CIs) and p values were obtained using bias-
corrected nonparametric bootstrap with 1,000 replicates. An additional indicator for 
observations occurring after a scanner upgrade was entered to adjust for potential upgrade-
induced change. 
 
Standard protocol approvals, registrations, and patient consents. 
The study was approved by the Joint Medical Ethics Committee of the National Hospital for 
Neurology and Neurosurgery and the Institute of Neurology, London, UK. We received 
written informed consent from all patients participating in the study. 
Twenty-one patients with PPMS were HLA-DRB1*15 positive and 20 were negative. No 
statistically significant differences in clinical or MRI variables were found between these 2 
patient groups at baseline (table 1). 
Results 
Both groups of patients progressed over time, as demonstrated by significant rates of 
changes in the EDSS score, 25-foot walk test, and 9-Hole Peg Test (table 2). There was a 
significant change in all of the brain MRI variables and spinal cord cross-sectional area over 
5 and 2 years, respectively, in both the allele-positive and -negative patients, with the 
exception of the NAWM PH MTR, which did not significantly change in either group. 
Changes in NAWM peak location and mean MTR and GM PH MTR in the allele-negative 
patients did not reach statistical significance (table 2). None of these parameters changed 
significantly over time in healthy controls7 (table e-1). 
When comparing the rate of changes between HLA-DRB1*15-positive and -negative 
patients, the allele-positive patients showed a greater decline in brain PH MTR for GM and 
NAWM than HLA-DRB1*15-negative patients (GM: by −1 × 10−5 percentage volumes/mo, 
95% CI −2 × 10−5 to −0.51 × 10−5, vs 0.041 × 10−5, 95% CI −1 × 10−5 to 1 × 10−5, p = 
0.004; NAWM: by −2 × 10−5 percentage volumes/mo, 95% CI −4 × 10−5 to 0.12 × 10−5 vs 
1 × 10−5, 95% CI −1 × 10−5 to 3 × 10−5, p = 0.004) when correcting for age and sex (table 
2). We also repeated the analyses adjusting for T2 lesion volume at baseline, to rule out that 
differences in monthly rates of change over time between groups were due to the difference 
in baseline T2 lesion volume between the 2 groups, which was, however, nonsignificantly 
greater in allele-positive patients than in allele-negative patients (see table 1). After adjusting 
for T2 lesion volume at baseline, the differences between genetic groups in monthly rates in 
MTR measures were still significant (for GM PH MTR: p = 0.011; for NAWM PH MTR: p = 
0.012). Similarly, the differences in monthly rates of changes in MTR measures remained 
significant when adjusting for baseline EDSS score (for GM PH MTR: p = 0.004; for NAWM 
PH MTR: p = 0.011). In addition, HLA-DRB1*15-positive patients showed a borderline 
significantly faster increase in brain T2 lesion volume than HLA-DRB1*15-negative patients 
over time (by 0.29 mL per month [95% CI 0.20–0.38] vs 0.21 [95% CI 0.13–0.30], p = 0.085) 
(figure, table 2). Also, this longitudinal model, which accounted for the disease duration of 
our patients, showed that allele-positive patients showed consistently higher T2 lesion 
volumes at all time points: average difference (along the whole follow-up) = 10.58 mL (95% 
CI 7.09–14.07), p < 0.001. 
There were no significant between-group differences in the rates of changes in NAWM and 
GM volumes, spinal cord cross-sectional area, and clinical scores (table 2). 
 
Discussion 
In this study, we found that carriage of HLA-DRB1*15 was associated with increases in the 
development of brain GM and white matter pathology, as reflected by reduced MTR, a trend 
toward increased T2 lesion load over 5 years, and greater T2 lesion volumes at each time 
point over the follow-up, in patients with early PPMS. 
 
At baseline, there were no statistically significant differences in MRI measures between 
HLA-DRB1*15-positive and -negative patients. However, allele-positive patients showed a 
more rapid MTR decrease over time than patients not carrying the allele (and healthy 
controls), indicating that allele-positive patients may have greater accumulation of brain 
microstructural damage over time. MTR reflects the amount of macromolecular structure 
within the CNS, through the quantification of the transfer of magnetization between 
macromolecule-bound and free water.15 MTR is sensitive to myelin content and axonal 
density,15 and a decrease in MTR can be expected where there is demyelination and axonal 
loss.15 Axonal loss, with a consequent decrease in both myelin content and axonal density, 
is a widespread pathologic process in the NAWM,16 and demyelinating lesions may be 
extensive in the cortical GM although not visible on MRI.17 
 
Close scrutiny of the behavior of different MTR-derived histogram parameters demonstrated 
a greater decline in the PH MTR for both the NAWM and GM in allele-positive patients than 
in the negative ones. PH MTR indicates the volume of tissue with the most frequently 
observed MTR value (within that tissue). Thus, a PH MTR decrease probably indicates loss 
of tissue homogeneity secondary to microstructural changes, because a wider range of MTR 
values within that tissue is observed. The finding of reduced tissue homogeneity in the 
absence of significant changes in MTR peak location (possibly reflecting less pronounced 
structural damage) in the allele-positive patients compared with the allele-negative patients 
may reflect changes in the cellular composition of the tissue, such as an increased number 
of activated microglial cells, which are known to be diffusely present in the NAWM and 
GM.18 
 
In our study, allele-positive patients showed a trend toward a faster increase in T2 lesion 
volume over time than allele-negative patients, and greater T2 lesion volumes at all time 
points over the follow-up after adjusting for disease duration, despite not finding crude 
(unadjusted) differences in T2 lesion volume between genetic groups at baseline. This could 
be attributable to the increased precision of our longitudinal models, which considered the 
disease duration of every patient. It could also be attributable to the fact that, at baseline, 
patients at higher risk of developing more lesions over time (i.e., allele-positive patients) 
might not have had the time to show these differences as compared with allele-negative 
patients, especially considering that our follow-up was longer than the reported mean 
disease duration at baseline (5 vs 3.5 years). In addition, because of our sample size, it is 
likely that our study was underpowered to detect these (possibly very small) differences 
between groups. 
 
We found that both genetic groups showed a significant development of brain atrophy over 
time, in contrast to healthy controls, who did not. However, there were no differences in the 
rates of GM or NAWM volume loss over time between genetic groups. Although somewhat 
surprising, these findings may have 2 interpretations. First, they suggest that MTR 
parameters are more sensitive to tissue damage progression over time than volume loss, at 
least in early PPMS.7 Second, the stronger association between MTR measures or T2 
lesion volume and HLA genes may reflect a greater role of these genes in affecting 
inflammatory pathways with consequent demyelination and decrease in MTR, rather than 
affecting neurodegenerative processes (and hence no greater extent of atrophy). In line with 
this hypothesis, we did not find a relationship between cord atrophy over time and HLA-
DRB1*15. Similarly, a recent study found an effect of HLA-DRB1*15 allele on inflammation 
and demyelination at the microscopic level, but not atrophy.5 In fact, the proteins encoded 
by HLA genes, which are considered as MS susceptibility genes, are involved in 
inflammatory pathways such as antigen presentation. In particular, the HLA-DRB1*15 allele 
is believed to enhance the presentation of myelin basic protein peptides to T cells, thus 
promoting the presence of autoreactive T cells against the myelin basic protein.4 In our 
study, there was no availability of spinal cord sequences to calculate the spinal cord lesion 
volume or number, so we limited our investigation of the spinal cord MRI to spinal cord 
cross-sectional area (or atrophy). Thus, we could not confirm the previously reported 
association between HLA-DRB1*15 allele and number of spinal cord lesions.19 
 
Regarding the lack of significant brain atrophy over time among controls, it is possible that 
this not only reflected the absence of disease, but also the fact that the controls were 
younger, on average, than the patients.20 
 
Despite a significantly greater decline in the brain GM and NAWM MTR in the allele-positive 
patients than in the allele-negative patients, there was no difference in disability progression 
between patient groups over time. This could be explained by the observation that in this 
cohort of early PPMS, MRI parameters predicted future disability7 rather than concurrent 
clinical changes, suggesting that a follow-up period longer than 5 years may be necessary to 
detect the clinical impact of the observed MTR changes. There may also be other factors—
genetic, epigenetic, or environmental—that influence neurodegeneration, and hence the rate 
of tissue loss and clinical progression, independently of HLA-DRB1*15 status. Finally, the 
clinical measures may lack power because of the relatively low sensitivity of currently used 
disability scales to clinical worsening. Moreover, longitudinal cognitive data, which reflect 
microscopic CNS tissue changes better than motor disability data,4,12 were not recorded, 
probably contributing to the absence of association between HLA-DRB1*15 status and 
disability. A possible limitation of this study, in addition to the rather small sample size, which 
implies a reduction in our power to detect significant differences between genetic groups, is 
that we could not explore a possible dose-response relationship between genotype and MRI 
features that would have supported causality because all allele-positive patients were 
heterozygous regarding HLA-DRB1*15. 
 
Although in this study we report a number of statistical tests, we did not think it would be 
appropriate to adjust for multiple comparisons because we examined a number of separate 
null hypotheses rather than one single null hypothesis, meaning that the risk of false-positive 
results is not increased despite the amount of tests performed.21,22 Lastly, even though the 
linear mixed models we have used tend to be robust to the effect of missing data under 
plausible assumptions, it should be noted that more severely affected patients were more 
likely to be missing at MRI, and any remaining bias in our results attributable to this would 
tend to render our results conservative, because these missing patients were also more 
likely to be allele positive. 
 
This study shows the influence of the HLA-DRB1*15 gene on the accumulation of 
microstructural damage in the brain, as detected in vivo by MTR and T2 lesions, at the 
earliest stages of PPMS, but not on brain atrophy and spinal cord atrophy. This finding might 
also have important practical implications, considering that patients with PPMS who have a 
greater risk of accumulation of brain pathology may need to be stratified for early and 
targeted therapeutic interventions. 
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Glossary 
CI confidence interval 
EDSS Expanded Disability Status Scale 
GM gray matter 
MS multiple sclerosis 
MTR magnetization transfer ratio 
NAWM normal-appearing white matter 
PH peak height 
PPMS primary progressive multiple sclerosis 
  
REFERENCES 
1. Compston A, Howard S. HLA typing in multiple sclerosis. Lancet 1982;2:661. 
[PubMed] [Google Scholar] 
2. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is 
associated with lower age at onset in multiple sclerosis. Ann Neurol 2000;48:211–219. 
[PubMed] [Google Scholar] 
3. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional 
composite as a clinical trial outcome measure. Brain 1999;122:871–882. [PubMed] [Google 
Scholar] 
4. Okuda DT, Srinivasan R, Oksenberg JR, et al. Genotype–phenotype correlations in 
multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy 
and MRI measures. Brain 2009;132:250–259. [PMC free article] [PubMed] [Google Scholar] 
5. DeLuca GC, Alterman R, Martin JL, et al. Casting light on multiple sclerosis heterogeneity: 
the role of HLA-DRB1 on spinal cord pathology. Brain 2013;136:1025–1034. 
[PubMed] [Google Scholar] 
6. Khaleeli Z, Altmann DR, Cercignani M, Ciccarelli O, Miller DH, Thompson 
AJ. Magnetization transfer ratio in gray matter: a potential surrogate marker for progression 
in early primary progressive multiple sclerosis. Arch Neurol 2008;65:1454–1459. 
[PubMed] [Google Scholar] 
7. Tur C, Khaleeli Z, Ciccarelli O, et al. Complementary roles of grey matter MTR and T2 
lesions in predicting progression in early PPMS. J Neurol Neurosurg 
Psychiatry 2011;82:423–428. [PubMed] [Google Scholar] 
8. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple sclerosis: 
a 5-year clinical and MR study. Brain 2003;126:2528–2536. [PubMed] [Google Scholar] 
9. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive 
multiple sclerosis: a position paper. Ann Neurol 2000;47:831–835. [PubMed] [Google 
Scholar] 
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability 
Status Scale (EDSS). Neurology 1983;33:1444–1452. [PubMed] [Google Scholar] 
11. Ramagopalan SV, Morris AP, Dyment DA, et al. The inheritance of resistance alleles in 
multiple sclerosis. PLoS Genet 2007;3:1607–1613. [PMC free article] [PubMed] [Google 
Scholar] 
12. Tur C, Penny S, Khaleeli Z, et al. Grey matter damage and overall cognitive impairment 
in primary progressive multiple sclerosis. Mult Scler 2011;17:1324–1332. [PubMed] [Google 
Scholar] 
13. Barker GJ, Tofts PS, Gass A. An interleaved sequence for accurate and reproducible 
clinical measurement of magnetization transfer ratio. Magn Reson Imaging 1996;14:403–
411. [PubMed] [Google Scholar] 
14. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple 
sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease 
progression. Brain 1996;119:701–708. [PubMed] [Google Scholar] 
15. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio 
and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56:407–415. 
[PubMed] [Google Scholar] 
16. Moll NM, Rietsch AM, Thomas S, et al. Multiple sclerosis normal-appearing white matter: 
pathology-imaging correlations. Ann Neurol 2011;70:764–773. [PMC free 
article] [PubMed] [Google Scholar] 
17. Chen JT, Easley K, Schneider C, et al. Clinically feasible MTR is sensitive to cortical 
demyelination in MS. Neurology 2013;80:246–252. [PMC free article] [PubMed] [Google 
Scholar] 
18. Lassmann H. Multiple sclerosis: lessons from molecular neuropathology. Exp 
Neurol Epub 2013 Dec 14. [PubMed] 
19. Sombekke MH, Lukas C, Crusius JB, et al. HLA-DRB1*1501 and spinal cord magnetic 
resonance imaging lesions in multiple sclerosis. Arch Neurol 2009;66:1531–1536. 
[PubMed] [Google Scholar] 
20. Jiang J, Sachdev P, Lipnicki DM, et al. A longitudinal study of brain atrophy over two 
years in community-dwelling older individuals. Neuroimage 2014;86:203–211. 
[PubMed] [Google Scholar] 
21. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236–
1238. [PMC free article] [PubMed] [Google Scholar] 
22. Rothman KJ. No adjustments are needed for multiple 
comparisons. Epidemiology 1990;1:43–46. [PubMed] [Google Scholar] 
 
  
FIGURES 
 
Figure. Raw and estimated (adjusted) rates of change in MRI measures in HLA-DRB1*15-
positive and -negative patients 
Raw (A, C) and estimated (B, D) values of GM PH MTR (in PV) (A, B), and NAWM PH MTR 
(in PV) (C, D) over time, for allele-positive and allele-negative patients. Allele-positive 
patients show a significantly greater decrease in PH MTR than allele-negative patients (p = 
0.004 for both, GM and NAWM PH MTR). GM = gray matter; MTR = magnetization transfer 
ratio; NAWM = normal-appearing white matter; PH = peak height; PV = percentage volumes. 
 
 
  
Tables 
 
Table 1. Clinical, demographic, and MRI characteristics of subjects at the study entry. 
Abbreviations: EDSS 5 Expanded Disability Status Scale; GM 5 gray matter; GMPF 5 gray 
matter parenchymal fraction; MTR 5 magnetization transfer 
ratio; NAWM 5 normal-appearing white matter; NAWMPF 5 NAWM parenchymal fraction; 9-
HPT 5 9-Hole Peg Test; PASAT 5 Paced Auditory Serial 
Addition Test; PH 5 peak height; PL 5 peak location; PU 5 percentage units; PV 5 
percentage volumes; T2LV 5 T2 lesion volume; TWT 5 25-foot walk test. 
Results are expressed as mean (SD), unless otherwise stated. No significant differences 
were observed between allele-positive and allele-negative patients. 
 
 Table 2. Monthly rates of change of clinical and MRI measures over the 5-year follow-up 
perioda and differences between HLA-DRB1*15-positive and -negative patients 
Abbreviations: CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; GM 5 
gray matter; GMPF 5 gray matter parenchymal fraction; MTR 5 
magnetization transfer ratio; NAWM 5 normal-appearing white matter; NAWMPF 5 NAWM 
parenchymal fraction; 9-HPT 5 9-Hole Peg Test; PASAT 5 
Paced Auditory Serial Addition Test; PH 5 peak height; PL 5 peak location; PU 5 percentage 
units; PV 5 percentage volumes; T2LV 5 T2 lesion volume; 
TWT 5 25-foot walk test. 
Results are expressed as estimated mean monthly rate of change of each MRI variable 
(95% CI), p value related to the change within each group. a The ratio of change of the 
spinal cord area is calculated over a period of 2 years (from baseline to 24-month follow-up). 
For the comparison between allele-positive and allele-negative patients: after adjusting for 
age and sex: b p , 0.1, c p , 0.01; after adjusting for age, sex, 
and T2 lesion volume at baseline: d p , 0.05; after adjusting for age, sex, and EDSS at 
baseline: e p , 0.05. 
